Lunai Bioworks (LNAI) Liabilities and Shareholders Equity (2011 - 2026)
Lunai Bioworks (LNAI) posted quarterly Liabilities and Shareholders Equity of $9.9 million for Q1 2026, down 91.62% year-over-year from $117.7 million in Q1 2025, and up 47.91% quarter-over-quarter from $6.7 million in Q4 2025.
Lunai Bioworks (LNAI) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Lunai Bioworks' Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $9.9 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 91.62% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $31.7 million (down 93.83% YoY), while the FY2025 annual figure was $8.2 million, down 94.95% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $9.9 million, up from $6.7 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $180.1 million in Q1 2022, with the low at $6.7 million in Q4 2025.
- The 5-year median for Liabilities and Shareholders Equity is $80.3 million (2022), against an average of $82.6 million.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity surged 179.81% in 2024, then sank 94.95% in 2025.
- Lunai Bioworks' Liabilities and Shareholders Equity stood at $80.3 million in 2022, then fell by 27.72% to $58.0 million in 2023, then soared by 91.91% to $111.3 million in 2024, then slumped by 94.01% to $6.7 million in 2025, then surged by 47.91% to $9.9 million in 2026.
- Business Quant data shows LNAI's Liabilities and Shareholders Equity at $9.9 million in Q1 2026, $6.7 million in Q4 2025, and $7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 9.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.86 Mn |
| Dec 31, 2025 | 6.67 Mn |
| Sep 30, 2025 | 6.96 Mn |
| Jun 30, 2025 | 8.23 Mn |
| Mar 31, 2025 | 117.73 Mn |
| Dec 31, 2024 | 111.34 Mn |
| Sep 30, 2024 | 121.83 Mn |
| Jun 30, 2024 | 163.13 Mn |
| Mar 31, 2024 | 178.09 Mn |
| Dec 31, 2023 | 58.02 Mn |
| Sep 30, 2023 | 57.56 Mn |
| Jun 30, 2023 | 58.30 Mn |
| Mar 31, 2023 | 78.73 Mn |
| Dec 31, 2022 | 80.27 Mn |
| Sep 30, 2022 | 83.07 Mn |
| Jun 30, 2022 | 84.63 Mn |
| Mar 31, 2022 | 180.10 Mn |
| Dec 31, 2021 | 183.14 Mn |
| Sep 30, 2021 | 184.06 Mn |
| Jun 30, 2021 | 189.61 Mn |